Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.67

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $8.6667.

A number of equities analysts have recently issued reports on GANX shares. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Finally, Roth Mkm reiterated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th.

Gain Therapeutics Price Performance

Shares of GANX opened at $2.61 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.52 and a quick ratio of 2.52. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The stock has a market cap of $100.39 million, a PE ratio of -4.28 and a beta of 0.05. The firm has a fifty day moving average price of $2.27 and a 200 day moving average price of $2.28.

Institutional Trading of Gain Therapeutics

A number of institutional investors have recently modified their holdings of the business. Marshall Wace LLP grew its stake in shares of Gain Therapeutics by 849.3% during the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after purchasing an additional 1,487,186 shares during the period. Potomac Capital Management Inc. acquired a new stake in shares of Gain Therapeutics in the fourth quarter valued at about $3,252,000. Geode Capital Management LLC boosted its holdings in Gain Therapeutics by 15.6% during the fourth quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock worth $1,282,000 after buying an additional 53,796 shares in the last quarter. Jane Street Group LLC grew its position in Gain Therapeutics by 234.5% during the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after buying an additional 169,878 shares during the period. Finally, State Street Corp grew its position in Gain Therapeutics by 72.9% during the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock worth $507,000 after buying an additional 66,400 shares during the period. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.